Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 2/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25493358 | 0.83 | GABRA1 (0.41) | GABRA1GABRB1LMNAARPARP14 | |
| SCHEMBL20697007 | 0.81 | CYP1A2 (0.42) | LMNAARPARP14SOS2CYP1A2 | |
| SCHEMBL27759814 | 0.80 | TRIM24 (0.31) | — | |
| SCHEMBL5673618 | 0.78 | GABRA1 (0.39) | GABRA1GABRB1PARP14SOS2 | |
| SCHEMBL24215575 | 0.76 | CD44 (0.39) | LMNAARIDO1HTR2AAHR | |
| SCHEMBL12244364 | 0.72 | SOS2 (0.54) | ARPARP14SOS2HTR2AAHR | |
| SCHEMBL31375034 | 0.71 | F7 (0.51) | CYP1A2 | |
| SCHEMBL672970 | 0.71 | TRIM24 (0.56) | LMNACYP1A2 | |
| SCHEMBL12244358 | 0.70 | HTR2A (0.55) | IDO1HTR2A | |
| SCHEMBL22308526 | 0.70 | PARP14 (0.32) | PARP14SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | GABRA1 2849/4885GABRB1 3630/4885LMNA 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.